Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock
Guardion Health Sciences (Nasdaq: GHSI) has announced a significant cash dividend of $5.00 per share of common stock. The company's Board of Directors declared this dividend for stockholders of record as of September 9, 2024, with the payment scheduled for September 23, 2024. This substantial dividend declaration suggests a strong financial position for Guardion and represents a notable return of value to shareholders. The announcement may have positive implications for investor confidence and could potentially impact the stock's performance in the near term.
Guardion Health Sciences (Nasdaq: GHSI) ha annunciato un significativo dividendo in contante di 5,00 $ per azione di azioni ordinarie. Il Consiglio di Amministrazione dell'azienda ha dichiarato questo dividendo per gli azionisti registrati al 9 settembre 2024, con pagamento previsto per il 23 settembre 2024. Questa sostanziale dichiarazione di dividendo suggerisce una forte posizione finanziaria per Guardion e rappresenta un notevole ritorno di valore per gli azionisti. L'annuncio potrebbe avere implicazioni positive per la fiducia degli investitori e potrebbe influenzare le performance delle azioni nel breve termine.
Guardion Health Sciences (Nasdaq: GHSI) ha anunciado un dividendo en efectivo significativo de $5.00 por acción de acciones ordinarias. La Junta Directiva de la compañía declaró este dividendo para los accionistas registrados a partir del 9 de septiembre de 2024, con el pago programado para el 23 de septiembre de 2024. Esta declaración de dividendo sustancial sugiere una sólida posición financiera para Guardion y representa un notable retorno de valor para los accionistas. El anuncio puede tener implicaciones positivas para la confianza de los inversores y podría afectar potencialmente el rendimiento de las acciones a corto plazo.
가디온 헬스 사이언스(나스닥: GHSI)가 보통주에 대해 주당 $5.00의 상당한 현금 배당금을 발표했습니다. 회사 이사회는 2024년 9월 9일 기준 주주들에게 이 배당금을 결정했으며, 지급은 2024년 9월 23일로 예정되어 있습니다. 이번 대규모 배당금 선언은 가디온의 강력한 재무 상태를 시사하며, 주주들에게 주목할 만한 가치 반환을 나타냅니다. 이번 발표는 투자자들의 신뢰에 긍정적인 영향을 미칠 수 있으며, 단기적으로 주가의 성과에 영향을 미칠 수 있습니다.
Guardion Health Sciences (Nasdaq: GHSI) a annoncé un dividende en espèces significatif de 5,00 $ par action d'actions ordinaires. Le Conseil d'administration de la société a déclaré ce dividende pour les actionnaires inscrits au 9 septembre 2024, avec un paiement prévu le 23 septembre 2024. Cette déclaration de dividende substantielle suggère une position financière solide pour Guardion et représente un retour de valeur notable pour les actionnaires. Cette annonce pourrait avoir des implications positives pour la confiance des investisseurs et pourrait potentiellement influencer la performance de l'action à court terme.
Guardion Health Sciences (Nasdaq: GHSI) hat eine bedeutende Barausschüttung von 5,00 $ pro Aktie an Stammaktien angekündigt. Der Vorstand des Unternehmens hat diese Dividende für Aktionäre, die am 9. September 2024 registriert sind, erklärt, wobei die Zahlung für den 23. September 2024 geplant ist. Diese umfangreiche Dividendenerklärung deutet auf eine starke finanzielle Lage von Guardion hin und stellt eine bemerkenswerte Wertschöpfung für die Aktionäre dar. Die Ankündigung könnte positive Auswirkungen auf das Vertrauen der Investoren haben und möglicherweise die Kursentwicklung der Aktien kurzfristig beeinflussen.
- Substantial cash dividend of $5.00 per share declared
- Indicates strong financial position and ability to return value to shareholders
- Potential boost to investor confidence and stock attractiveness
- Large dividend payout may impact cash reserves for future operations or investments
- Potential short-term decrease in stock price post-dividend payment
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash dividend in an amount equal to
Forward-Looking Statements
The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.
These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the completion of the Company’s Plan of Liquidation and Dissolution, the use of the proceeds received from the sale of the Viactiv business, the Company’s decision to continue to fund or wind-down its operations subsequent to the sale of the Viactiv business, the sale or other disposition of the Company’s ocular healthcare business, the exploration, timing and feasibility of alternatives to the Company’s Plan of Liquidation and Dissolution, the payment of a cash dividend on the Company’s common stock supply chain disruptions, a potential recession and the condition of the economy in general, the Company’s ability to successfully market its remaining products and inventory, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.
Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about Guardion Health Sciences, Inc., Contact:
Phone: 1-800 873-5141 Ext 208
FAQ
What is the amount of the cash dividend declared by Guardion Health Sciences (GHSI)?
When is the record date for Guardion Health Sciences' (GHSI) dividend?
What is the payment date for Guardion Health Sciences' (GHSI) $5.00 dividend?
How might the $5.00 dividend affect Guardion Health Sciences' (GHSI) stock price?
